focus -WSS

focus

author：explore 2025-09-30 17:28:56 - browse：77

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Food makers tried to stack nutrition panel with preferred experts

focus

WSS

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Acelyrin, a rare IPO success, stumbles in its first big test

Telehealth for opioid use disorder is lifesaving

EQRx, failed developer of low

Food makers to regulators: Ultra

New safety details link Apellis eye drug to rare cases of blindness

leisure time

focus

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

How housing is health care on Long Island

Medical records are filled with copy

FDA approves updated Covid vaccines

Jerome Adams on the need for new antivirals for Covid

Acelyrin, a rare IPO success, stumbles in its first big test

Wildfire smoke exposes gaps in outdoor worker protections

National panel will explore requiring free Covid tests

Hepatitis C has a cure — but many Americans still lack access to it

What the airline industry can learn from medicine

focus

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

FDA panel endorses Alnylam’s heart drug — after picking it apart

Physician groups backed by private equity giant lobby on mergers

New safety details link Apellis eye drug to rare cases of blindness

How to make the FDA’s new prescription one

The high personal cost of affirmative action for Black doctors

focus

focus

leisure time

hotspot